SUMMARY A randomised double-blind placebo-controlled trial of phenylethylmalonamide, the major metabolite of primidone was performed in eight patients with essential tremor. Phenylethylmalonamide was given in a daily dose of 400 mg for one week and 800 mg for a second week. The compound had no statistically significant effect on the amplitude of tremor assessed by an accelerometric method, tests of performance, clinical evaluation and patient self assessment. No side effects occurred. Serum levels of phenylethylmalonamide on a daily dose of 400 mg were 11-27 ,ug/ml and on 800 mg daily were ]6-48 5 pg/ml.
Method
Eight male patients with moderate to severe essential tremor aged 28-69 years (mean 58) and weighing between 55-80 kg (mean 70) who were attending the out-patient clinic at the National Hospital, Queen Square, took part in the study. All had been symptomatic for at least 5 years and in three there was a family history of tremor involving the hands or head or both. In these patients the dominant peak frequency of tremor in the more involved hand ranged from 4-2 to 7-8 Hz (mean 5 9). None of the patients was receiving drug treatment for tremor at the time of the trial. This study was double blind and placebo controlled. PEMA was supplied in powder form by Desitin-Werk (Hamberg) and prepared for oral administration in soft gelatin capsules. Each patient was given PEMA or matched placebo for two weeks respectively in a randomised order according to a cross-over design. Blood samples were collected at the end of each recording session. PEMA was determined in serum by gas-liquid chromatography with flame-ionisation detection. In brief after acidification of the serum and addition of hexobarbitone as internal standard, PEMA was extracted in 8 ml of chloroform. After evaporation of the solvent, the final residuum was dissolved in 50 ,ul of chloroform and 1-2 pul were injected into the gas-chromatograph fitted with a glass column (159 cm x 3 mm ID), packed with GP2 % SP-2510-DA on 100/120 mesh Supelcoport (Supelchem Inc, Bellefonte). Chromatograph conditions were as follows: oven temperature 215°C, detector and injection part 250°C. Nitrogen was used as the carrier gas.
Results
The results were subjected to a three factor repeated measures analysis of variance, with week, drug and hand (left and right separately) as the factors. Computer analysis was performed using BMDP 2V version 1977 
